- Home
- SBET vs QNRX Comparison
SBET vs QNRX Comparison
Compare SBET & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBET | QNRX |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 14.5M |
| IPO Year | 2025 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SBET | QNRX |
|---|---|---|
| Price | $6.52 | $6.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $19.17 | N/A |
| AVG Volume (30 Days) | ★ 5.7M | 110.7K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,055,000.00 | N/A |
| Revenue This Year | $109.16 | N/A |
| Revenue Next Year | $14.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 666.04 | N/A |
| 52 Week Low | $0.19 | $5.05 |
| 52 Week High | $124.12 | $41.80 |
Technical Indicators
Market Signals| Indicator | SBET | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.53 | 40.83 |
| Support Level | $6.05 | N/A |
| Resistance Level | $8.34 | $7.80 |
| Average True Range (ATR) | 0.38 | 0.92 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 30.58 | 13.05 |
Price Performance
Historical ComparisonAbout SBET SharpLink Gaming Ltd.
SharpLink Gaming Inc is one of the world's largest publicly traded companies to adopt ETH as its primary treasury reserve asset - a move that aligns the Company with the future of digital capital and gives investors direct exposure to Ethereum, the world's smart-contract platform and second largest digital asset.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.